에 대한 최신 뉴스 Immuneering (NASDAQ:IMRX) 주식

IMMUNEERING CORP - CLASS A

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Nvidia,Logo,On,Mobile,Phone,Screen,Company,Shares,Rise,Or

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

Immuneering Corporation - Class A Common Stock

Immuneering Corp

American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 60 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $49.68 thousand which missed the analyst consensus estimate of $1.30 million by 96.18 percent. This is a 25.19 percent decrease over sales of $66.40 thousand the same period last year.

Earnings

Earnings Misses

News

AREC

American Res Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $49.68K Miss $1.30M Estimate

<a href="https://asia.nikkei.com/Business/Finance/Mizuho-and-Mercer-to-team-up-to-offer-asset-management-services">https://asia.nikkei.com/Business/Finance/Mizuho-and-Mercer-to-team-up-to-offer-asset-management-services</a>

General

'Mizuho and Mercer to team up to offer asset management services'- Nikkei Asia

Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) .

Guidance

QFIN

Qifu Technology forecasts Q2 2025 net income of RMB1.65B -1.75B and non-GAAP net income of RMB1.75B-1.85B.

Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.72 by 8.14 percent. This is a 77.14 percent increase over earnings of $1.05 per share from the same period last year. The company reported quarterly sales of $646.40 million which beat the analyst consensus estimate of $615.60 million by 5.00 percent. This is a 12.38 percent increase over sales of $575.21 million the same period last year.

Earnings Beats

Qifu Technology Q1 Adj. EPS $1.86 Beats $1.72 Estimate, Sales $646.40M Beat $615.60M Estimate

Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) reported quarterly earnings of $0.82 per share which missed the analyst consensus estimate of $0.86 by 4.65 percent. This is a 1.2 percent decrease over earnings of $0.83 per share from the same period last year. The company reported quarterly sales of $1.91 billion which met the analyst consensus estimate. This is a 15.69 percent increase over sales of $1.65 billion the same period last year.

TCOM

Trip.com Group Q1 Adj. EPS $0.82 Misses $0.86 Estimate, Sales $1.91B Inline

11 analysts have shared their evaluations of WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $70.55, a high estimate of $80.00, and a low estimate of $62.00. Observing a 8.39% increase, the current average has risen from the previous average price target of $65.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1747692089_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of WR Berkley by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$62.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$66.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$62.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$69.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$73.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WR Berkley. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of WR Berkley compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of WR Berkley's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into WR Berkley's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WRB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WR Berkley analyst ratings.</a>
<h2>Unveiling the Story Behind WR Berkley</h2>
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
<h3>WR Berkley's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, WR Berkley showcased positive performance, achieving a revenue growth rate of 7.89% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: WR Berkley's net margin excels beyond industry benchmarks, reaching 11.84%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): WR Berkley's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.82%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): WR Berkley's ROA stands out, surpassing industry averages. With an impressive ROA of 1.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: WR Berkley's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: WR Berkley Through The Eyes Of 11 Analysts

In the last three months, 11 analysts have published ratings on Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Travelers Companies, presenting an average target of $273.64, a high estimate of $296.00, and a low estimate of $247.00. Witnessing a positive shift, the current average has risen by 3.01% from the previous average price target of $265.64.
<img src="https://www.benzinga.com/files/images/story/2025/1747692078_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Travelers Companies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$269.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$296.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$270.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$267.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$274.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$247.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$271.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$286.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travelers Companies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Travelers Companies compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Travelers Companies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Travelers Companies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TRV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Travelers Companies analyst ratings.</a>
<h2>All You Need to Know About Travelers Companies</h2>
Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance.
<h3>Key Indicators: Travelers Companies's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Travelers Companies's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.18%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Travelers Companies's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.4%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Travelers Companies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.28, Travelers Companies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 11 Analysts Discuss Travelers Companies Stock

Analysts' ratings for JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for JM Smucker, revealing an average target of $124.8, a high estimate of $134.00, and a low estimate of $119.00. Observing a 0.1% increase, the current average has risen from the previous average price target of $124.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1747692069_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of JM Smucker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Palmer</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$128.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$134.00</td>
<td>-</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$123.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$119.00</td>
<td>$123.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to JM Smucker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of JM Smucker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of JM Smucker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SJM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on JM Smucker analyst ratings.</a>
<h2>Delving into JM Smucker's Background</h2>
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (78% of fiscal 2024 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of Hostess and international (primarily Canada). Retail coffee is its largest category (33% of sales) with brands Folgers and Dunkin'. Pet foods (22% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from consumer foods, primarily peanut butter and jelly, through brands Jif and Smucker's. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
<h3>Breaking Down JM Smucker's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, JM Smucker faced challenges, resulting in a decline of approximately -1.94% in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: JM Smucker's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -30.3%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): JM Smucker's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -9.11%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.45%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.15, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For JM Smucker's Future

In the current market session, PG&amp;E Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) share price is at $17.86, after a 0.05% drop. Over the past month, the stock spiked by 1.72%, but over the past year, it actually decreased by 6.24%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747692068_0.png" alt="Past Year Chart" />

<h3>PG&amp;E P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
PG&amp;E has a lower P/E than the aggregate P/E of 19.67 of the Electric Utilities industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747692068_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

Price Over Earnings Overview: PG&E

Ratings for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $103.06, a high estimate of $140.00, and a low estimate of $60.00. This current average represents a 19.85% decrease from the previous average price target of $128.59. 
<img src="https://www.benzinga.com/files/images/story/2025/1747692061_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Marvell Tech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Thomas O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$90.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$122.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Harsh Kumar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Thomas O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Marvell Tech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Marvell Tech compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Marvell Tech's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Marvell Tech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRVL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Marvell Tech analyst ratings.</a>
<h2>About Marvell Tech</h2>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
<h3>Financial Insights: Marvell Tech</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Marvell Tech displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 27.4%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Marvell Tech's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 11.02%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Marvell Tech's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.49%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Marvell Tech's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.0%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.32, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

Demystifying Marvell Tech: Insights From 18 Analyst Reviews

Across the recent three months, 10 analysts have shared their insights on PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.85, along with a high estimate of $26.00 and a low estimate of $16.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.79%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747692047_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive PENN Entertainment is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jason Tilchen</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.50</td>
<td>$17.50</td>
</tr>
<tr>
<td>Joseph Stauff</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$23.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to PENN Entertainment. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PENN Entertainment compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of PENN Entertainment's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into PENN Entertainment's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PENN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PENN Entertainment analyst ratings.</a>
<h2>About PENN Entertainment</h2>
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
<h3>Key Indicators: PENN Entertainment's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: PENN Entertainment's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 4.08%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: PENN Entertainment's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.68%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): PENN Entertainment's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.83% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): PENN Entertainment's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.74%, the company may face hurdles in achieving optimal financial returns.
Debt Management: PENN Entertainment's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.7.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PENN

10 Analysts Assess PENN Entertainment: What You Need To Know

10 analysts have shared their evaluations of BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for BorgWarner, presenting an average target of $34.9, a high estimate of $44.00, and a low estimate of $29.00. A 5.93% drop is evident in the current average compared to the previous average price target of $37.10. 
<img src="https://www.benzinga.com/files/images/story/2025/1747692028_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of BorgWarner among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>David Leiker</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Ronald Jewsikow</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Leiker</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Alexander Potter</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BorgWarner. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BorgWarner compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into BorgWarner's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BWA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BorgWarner analyst ratings.</a>
<h2>Delving into BorgWarner's Background</h2>
BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2023, 25% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.
<h3>Unraveling the Financial Story of BorgWarner</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3M period, BorgWarner faced challenges, resulting in a decline of approximately -2.23% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.47%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): BorgWarner's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.79%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): BorgWarner's ROA stands out, surpassing industry averages. With an impressive ROA of 1.13%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.71.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing BorgWarner: Insights From 10 Financial Analysts

Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 12.73% on an annualized basis producing an average annual return of 27.75%. Currently, Goldman Sachs Group has a market capitalization of $191.20 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $339.98 today based on a price of $612.75 for GS at the time of writing.
<h3>Goldman Sachs Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747692015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Goldman Sachs Group 5 Years Ago Would Be Worth This Much Today

BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) reported quarterly losses of $(0.14) per share. This is a 61.11 percent increase over losses of $(0.36) per share from the same period last year.

BSGM

BioSig Technologies Q1 EPS $(0.14) Up From $(0.36) YoY; Revenue 0.00 vs 14K YoY

Barstool Sports founder Dave Portnoy is no stranger to <a href="https://www.benzinga.com/general/sports-betting/24/06/39382135/portnoy-wins-big-with-boston-celtics-nba-championship-rapper-drake-loses-500k-and-could-lo">placing large wagers </a>on top sports outcomes and he made sure to get in on the action for the first Indiana Fever WNBA game of the 2025 season as a Caitlin Clark fan.
Portnoy's winnings were large and might illustrate the gap between WNBA and NBA salaries once again.
What Happened: The Fever were dominant in their first game of the season beating the Chicago Sky 93-58, a win that might have been heavily bet <a href="https://www.benzinga.com/general/sports-betting/24/04/38276225/caitlin-clark-is-no-1-pick-in-wnba-draft-media-stocks-sportsbooks-to-watch-as-iowa-star-go">on at sportsbooks </a>with Clark and Angel Reese featured, two former college basketball stars now in their second years in the WNBA.
Clark finished the game with 20 points, 10 rebounds and 10 assists, marking her third career triple double, a feat that occurs when a player has 10 or more in three different stat categories.
Portnoy <a href="https://x.com/stoolpresidente/status/1923859511560847516">predicted </a>Clark's triple double before the game, placing a $25,000 wager with DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), a sportsbook he is partnered.
With the triple double, Portnoy's bet at odds of +1,300 paid out a total of $350,000 for a $325,000 profit.
The huge win isn't the largest by Portnoy and one of many examples of his large bets on sports contests.
The profit amount quickly took another direction on social media with people comparing the winnings to the WNBA salary of Clark and how it <a href="https://www.benzinga.com/markets/cannabis/22/08/28390094/this-lebron-james-stat-could-explain-why-brittney-griner-was-playing-in-russia">stacks up against the NBA. </a>
Clark, the first overall pick of the 2024 WNBA draft, had a salary of $76,535 in her rookie season and is set to make $78,066 in her second season. She will be paid $85,873 and $97,583 for the 2026 and 2027 seasons, respectively.
Clark's four-year rookie contract is worth $338,056. This means that Portnoy's profit on one Clark bet from her first 2025 game made him almost as much as the WNBA will pay Clark for her first four seasons in the league.
For comparison, the number one overall NBA pick in the 2024 draft Zaccharie Risacher earned a four-year $57 million contract.
While most WNBA players will earn less than NBA players, Clark will be one of the top earners thanks to endorsement deals. As <a href="https://www.benzinga.com/general/sports/24/04/38409019/caitlin-clark-nears-28m-nike-endorsement-sneaker-deal-45-times-her-wnba-salary">Benzinga previously reported,</a> Clark landed a $28 million eight-year deal with Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>). That deal pays out over 45x the first-year salary for Clark.
According to <a href="https://www.sportico.com/personalities/athletes/2024/caitlin-clark-wnba-salary-pay-endorsement-earnings-1234819038/">Sportico</a>, Clark is one of the highest-paid female athletes with $11 million in earnings from endorsements. Along with Nike, Clark as deals with the likes of Gatorade, State Farm, Wilson, Xfinity and Panini.
Read Also: <a href="https://www.benzinga.com/general/sports/25/05/45303072/draftkings-q1-earnings-highlights-revenue-miss-eps-miss-guidance-cut-after-bettors-beat-the-house">DraftKings Q1 Earnings Highlights: Revenue Miss, EPS Miss, Guidance Cut After Bettors Beat The House</a>
What's Next: Expectations are high for the Indiana Fever and Clark in the 2025 season. The team ranks second in betting odds to win the WNBA championship with odds of +340, trailing only the defending champion New York Liberty at +225 according to sportsbook DraftKings. 
Clark is the favorite to win the WNBA MVP at odds of +165, ranking ahead of last year's runner-up Napheesa Collier (+250) and last year's winner A'ja Wilson (+275).
Portnoy said the Fever are the team to beat and Clark could go on to win the MVP championship.
"Fever look great. Caitlin Clark looks like she's gonna be the MVP of the league."
Betting $100 on the Fever to win the WNBA Championship will pay out a profit of $340 if Portnoy is right. Betting $100 on Clark to win MVP would pay out a profit of $165.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/sports-betting/24/02/37239149/exclusive-draftkings-partnership-with-barstool-sports-getting-the-band-together-ceo-says-h">EXCLUSIVE: DraftKings Partnership With Barstool Sports &#8216;Getting The Band Together,&#8217; CEO Says — How New Deal, Jackpocket Acquisition Can Power Growth</a></li>
</ul>
Photos: Shutterstock

Sports Betting

Sports

DKNG

Dave Portnoy's Big Caitlin Clark Bet Profits $325K, Nearly The Same Amount Of WNBA Star's Four-Year Salary

<a href="https://www.bloomberg.com/news/articles/2025-05-19/nike-lays-off-some-workers-in-shakeup-of-technology-division?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-19/nike-lays-off-some-workers-in-shakeup-of-technology-division?embedded-checkout=true</a>

'Nike Lays Off Some Workers in Shakeup of Technology Division'- Bloomberg

<a href="https://www.reuters.com/business/autos-transportation/gm-stop-exporting-vehicles-us-china-company-says-2025-05-19/#:~:text=DETROIT%2C%20May%2019%20(Reuters),United%20States%2C%20the%20company%20said">https://www.reuters.com/business/autos-transportation/gm-stop-exporting-vehicles-us-china-company-says-2025-05-19/#:~:text=DETROIT%2C%20May%2019%20(Reuters),United%20States%2C%20the%20company%20said</a>

'GM to stop exporting vehicles from US to China, company says'- Reuters

Sunrise Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNRE#NASDAQ">SNRE</a>) reported Q1 EPS CHF 0.00; Sales CHF 722.1M

SNRE

Sunrise Communications Q1 EPS CHF 0.00; Sales CHF 722.1M

Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) has outperformed the market over the past 5 years by 4.58% on an annualized basis producing an average annual return of 19.6%. Currently, Option Care Health has a market capitalization of $5.42 billion. 
Buying $1000 In OPCH: If an investor had bought $1000 of OPCH stock 5 years ago, it would be worth $2,371.19 today based on a price of $33.09 for OPCH at the time of writing.
<h3>Option Care Health's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747691169_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OPCH

$1000 Invested In Option Care Health 5 Years Ago Would Be Worth This Much Today

After an impressive run over the first four months of the year, exchange-traded funds (ETFs) that invest in Treasury <a href="https://www.benzinga.com/etfs">Inflation-Protected Securities</a>, or TIPS, are now losing steam. Reason: inflation expectations, which climbed in recent months amid fears that the Trump administration&#8217;s tariffs will push up prices, have moderated somewhat, The Vanguard Short-Term Inflation-Protected Securities ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTIP#NASDAQ">VTIP</a>) has retreated about 0.75% from a high in early May, while the broader iShares TIPS Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIP#NYSE">TIP</a>) has fallen about 2.3% from its April peak. These are declines that have occurred in the context of a reset of inflation and bond-market conditions on the heels of a wave of mixed economic signals and a late-cycle credit rating shock.
Also Read:<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45501637/stocks-mixed-treasury-bonds-slip-on-moodys-us-downgrade-whats-driving-markets-monday"> Stocks Mixed, Treasury Bonds Slip On Moody&#8217;s US Downgrade: What&#8217;s Driving Markets Monday?</a>
Inflation Expectations Cool
The TIPS retreat coincides with a moderation in inflation expectations after President Donald Trump rolled back or paused most of the elevated tariff rates announced earlier. A sustained decline in the U.S. headline inflation rate also helped temper anxiety over prices. The headline inflation rate fell to 2.3% in April, which was the lowest level in over four years. Inflation breakeven rates have also moderated. The 5-Year TIPS Breakeven Rate has dropped to 2.42% from its February high of 2.66%. The 10-Year Breakeven Rate is at around 2.34%, a decline from this year&#8217;s high of 2.46% back in February, per FRED <a href="https://fred.stlouisfed.org/graph/?id=T5YIE,T10YIE,T5YIFR">data</a>.
Moody&#8217;s Downgrade Changes Treasury Dynamics
Adding to the squeeze on TIPS ETFs is a sudden surge in real yields, led by <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45500872/30-year-treasury-yields-hit-5-what-that-means-for-stocks">Moody&#8217;s Ratings downgrade of the U.S. sovereign credit rating from Aaa to Aa1</a>. On Monday afternoon, the 10-year Treasury yield was hovering at 4.45%. The 30-year yield also rose to 4.9%.
According to Bloomberg, Franklin Templeton&#8217;s Max Gokhman issued a warning of an eventual &#8220;bear steepener spiral&#8221; as institutional investors begin to shift out of long-dated Treasuries as fears about fiscal unsustainability and higher net interest burdens continue to grow.
Outlook: TIPS In A Tight Place
The near-term outlook for TIPS continues to be pinched by two headwinds: cooling inflation expectations, which reduce the attractiveness of inflation-indexed bonds, and increasing real yields, which debase the market value of TIPS, particularly longer-duration ones like TIP.
Unless inflation reaccelerates or a bond market turmoil inspires a flight to safety, TIPS ETFs can continue to lag relative to nominal Treasuries and equity-linked inflation hedges.
Inflation is no longer the villain, it&#8217;s the Treasury market&#8217;s own internal contradictions that are roiling the stage.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45503887/quantum-vs-ai-nvidias-next-big-bet-could-supercharge-these-2-etfs">Quantum Vs AI: Nvidia&#8217;s Next Big Bet Could Supercharge These 2 ETFs</a></li>
</ul>
Photo: Shutterstock

Bonds

Specialty ETFs

ETFs

VTIP

TIPS In Trouble: Why Inflation-Protected Bond ETFs Are Losing Their Spark

Opinion

Press Releases

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)

Management

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Health Care

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Corporation Announces Grant of Inducement Award

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

CRGX

ONCY

RNXT

RPTX

TSX:ONC

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

bluebird bio

Biomea Fusion

Celularity

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Forte Biosciences

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immix Biopharma

MAIA Biotechnology

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Renovaro

Rein Therapeutics

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

Shattuck Labs

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Oppenheimer

Chardan Capital

Needham

Mizuho

Jefferies

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">개별 종목</a>에 대한 최신 뉴스를 확인할 수 있는 소스이다.
2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.
1. 엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>현재 가격: $121.44</li>
<li>52주 최고가/최저가: $39.23 ~ $140.76</li>
<li>연초 대비 수익률: +152.1%</li>
<li><a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple" target="_blank" rel="noopener" data-google-interstitial="false">6월</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow" target="_blank" rel="noopener" data-google-interstitial="false">7월</a>/<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noopener" data-google-interstitial="false">8월 </a>순위: 1위/2위/1위</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>현재 가격: $573.76</li>
<li>52주 최고가/최저가: $409.22 ~ $574.71</li>
<li>연초 대비 수익률: +21.4%</li>
<li>6월/7월/8월 순위: 3위/3위/2위</li>
</ul>
3. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>현재 가격: $261.63</li>
<li>52주 최고가/최저가: $138.80 ~ $271.00</li>
<li>연초 대비 수익률: +5.3%</li>
<li>6월/7월/8월 순위: 4위/1위/3위</li>
</ul>
4. 애플 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>현재 가격: $233.00</li>
<li>52주 최고가/최저가: $164.08 ~ $237.23</li>
<li>연초 대비 수익률: +25.5%</li>
<li>6월/7월/8월 순위: 5위/7위/6위</li>
</ul>
5. 휠러 리얼 에스테이트 인베스트 트러스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>)
<ul>
<li>현재 가격: $8.09</li>
<li>52주 최고가/최저가: $2.90 ~ $1,126.80</li>
<li>연초 대비 수익률: -92.8%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
6. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>현재 가격: $488.07</li>
<li>52주 최고가/최저가: $342.35 ~ $503.52</li>
<li>연초 대비 수익률: +21.2%</li>
<li>6월/7월/8월 순위: 11위/11위/9위</li>
</ul>
7. 슈퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>현재 가격: $416.40</li>
<li>52주 최고가/최저가: $226.59 ~ $1,229.00</li>
<li>연초 대비 수익률: +45.9%</li>
<li>6월/7월/8월 순위: 10위/19위/4위</li>
</ul>
8. 갈메드 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>)
<ul>
<li>현재 가격: $6.86</li>
<li>52주 최고가/최저가: $2.73 ~ $23.80</li>
<li>연초 대비 수익률: +29.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
9. 인텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)
<ul>
<li>현재 가격: $23.46</li>
<li>52주 최고가/최저가: $18.51 ~ $51.28</li>
<li>연초 대비 수익률: -50.9%</li>
<li>6월/7월/8월 순위: 20위 미만</li>
</ul>
10. 인튜이티브 머신스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
<ul>
<li>현재 가격: $8.05</li>
<li>52주 최고가/최저가: $2.09 ~ $13.25</li>
<li>연초 대비 수익률: +241.1%</li>
<li>6월/7월/8월 순위: 20위 미만/20위 미만/20위</li>
</ul>
순위 밖의 주식들: 다음 주식들이 2024년 9월에 Benzinga Pro에서 11위에서 20위까지 가장 많이 검색된 종목들다.
11. 서밋 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)
12. 팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
13. 마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
14. 테논 메디컬 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>)
15. CN 에너지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>)
16. 취후오 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QH#NASDAQ">QH</a>)
17. 엔드라 라이프 사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>):
18. 어플라이드 디지털 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>)
19. 이뮤니어링 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>)
20. 트럼프 미디어 앤 테크놀로지 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)
중요성 (Why It's Important): 엔비디아는 9월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식으로 다시 한번 선정되었다. 이 주식은 2월 이후로 매달 1위 또는 2위를 기록하고 있으며, 때때로 SPY 또는 테슬라와 교대로 1위에 올랐다.
SPDR S&amp;P 500 ETF Trust는 9월에 S&amp;P 500 추적 지수가 사상 최고치를 기록하면서 2위를 차지했다.
테슬라는 7월에 1위를 차지한 이후 두 주 연속 3위를 기록했다. 이 주식은 2024년 동안 매달 검색된 상위 4개의 주식 중 하나로 자리 잡았다.
9월의 큰 관심은 신규 진입 주식들과 순위에서 떨어진 주식들이었다.
신규 진입자로는 휠러 리얼 에스테이트, 갈메드, 인텔 및 인튜이티브가 포함되었다. 이 4개 주식 중에서 인튜이티브만이 지난 3개월 간 상위 20위에 랭크된 바 있다. 이 신규 진입자들은 모두 지난달에 주식을 크게 변동시킨 촉매제가 있었다.
11위에서 20위까지의 목록에서도 이전 달과는 모든 주식이 달랐으며 인튜이티브는 상위 10위로 올라갔고, 팔란티어는 7위에서 12위로 하락했으며 나머지 주식들은 모두 상위 20위에 신규로 진입했다.
상위 20위의 하위 주식들 중 일부는 주가가 $5 이하로 거래되는 저가 주식들이며, 이들 주식은 큰 변동성을 보이며 Benzinga 트레이더들의 관심이 증가했다.
상위 20위에 이름 인지도로 들어온 큰 회사는 트럼프 미디어 앤 테크놀로지 그룹으로, 전 대통령 도널드 트럼프가 공동 설립자이다. 이 주식은 2024년 선거 주기 동안 매우 변동성이 컸다.
상위 10위에서 떨어진 주식들은 루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>), 어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), 지오백스 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) 및 앞서 언급한 팔란티어이다.
상위 20위에서 빠진 다른 큰 이름들은 8월에 13위였던 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)으로, 24위로 하락하여 리스트에 아슬아슬하게 들지 못했다.
메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 상위 20위에 자주 올라온 주식으로 8월에는 15위였으나 상위 20위에서 제외되었다.
전반적으로 9월에는 8월과 같은 상위 10개의 종목이 6개 있었고, 8월의 상위 20개 종목 중 8개가 포함되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/07/39603613/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-first-half-2024-where-do-nvidia-tesla-pala">독점: 2024년 상반기 가장 많이 검색된 종목 TOP 10 – 엔비디아, 테슬라, 팔란티어, 게임스탑의 순위는?</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Immuneering

뉴스

에 대한 최신 뉴스 Immuneering (NASDAQ:IMRX) 주식

수요일, 10월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌